Mesoblast FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Mesoblast Limited (NASDAQ:MESO - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Mesoblast in a note issued to investors on Monday, March 31st. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.71) per share for the year, down from their prior estimate of ($0.70). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Mesoblast's current full-year earnings is ($0.70) per share.

Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. Piper Sandler reaffirmed an "overweight" rating and set a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Mesoblast currently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Mesoblast Price Performance

Mesoblast stock traded down $1.03 during midday trading on Wednesday, reaching $10.57. 344,999 shares of the stock traded hands, compared to its average volume of 290,702. Mesoblast has a fifty-two week low of $4.60 and a fifty-two week high of $22.00. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average price of $15.69 and a two-hundred day moving average price of $13.35.

Institutional Trading of Mesoblast

A number of institutional investors have recently made changes to their positions in MESO. Lindbrook Capital LLC raised its holdings in Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after purchasing an additional 901 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock valued at $133,000 after purchasing an additional 1,213 shares during the period. R Squared Ltd bought a new stake in shares of Mesoblast in the 4th quarter worth $30,000. Prosperity Wealth Management Inc. lifted its holdings in shares of Mesoblast by 2.0% in the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock valued at $1,846,000 after buying an additional 1,795 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in Mesoblast by 41.1% during the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after buying an additional 1,891 shares in the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.